Goldman Sachs downgraded Thoratec (NASDAQ: THOR) from Conviction Buy to Buy with a price target of $42.00 (from $46.00). The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE